RxDoctor Payments Data

Gargi Patel

Allergy & Immunology · Piscataway, NJNPI 1740727411

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (43.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Ionis Pharmaceuticals, Inc. at 44.9% of the total. 2025 is the largest year on record at $9,414, more than ten times the $49 reported in 2019.

$12,445in general payments, 2019–2025

Across 279 payments — averaging $44.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ionis Pharmaceuticals, Inc.$6K
  • Sanofi$3K
  • AstraZeneca$602
  • GSK$462
  • Genentech USA, Inc.$394
  • Novartis$235
  • plus $2K from 24 others

What the payments were for

  • Consulting fees$1,71914%
  • Speaking & faculty fees$5,40043%
  • Food & beverage$5,23842%
  • Education$881%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,445 in reported general payments places this provider in the 75th percentile of 135 allergy & immunology providers in New Jersey.

See all allergy & immunology providers in New Jersey

Medicare billing

Part B allowed, 2024
$16,989
Medicare patients
62
Services billed
683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-5021$222,206
XolairOmalizumab41$131,694
Dupixent SyringeDupilumab26$101,661
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$10,727
Breo ElliptaFluticasone/Vilanterol18$6,728
Arnuity ElliptaFluticasone Furoate15$4,067
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,294
Fluticasone Propionate52$809
Azelastine Hcl27$502
Levocetirizine Dihydrochloride34$459
Albuterol Sulfate HfaAlbuterol Sulfate23$438
Montelukast Sodium21$344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHizentra$179$222,20621 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$462$21,52144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 135 allergy & immunology providers in New Jersey.

Other allergy & immunology in Piscataway

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →